102 related articles for article (PubMed ID: 2045866)
1. Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis.
Faradji A; Bohbot A; Frost H; Schmitt-Goguel M; Siffert JC; Dufour P; Eber M; Lallot C; Wiesel ML; Bergerat JP
J Clin Oncol; 1991 Jul; 9(7):1251-60. PubMed ID: 2045866
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
Faradji A; Bohbot A; Schmitt-Goguel M; Roeslin N; Dumont S; Wiesel ML; Lallot C; Eber M; Bartholeyns J; Poindron P
Cancer Immunol Immunother; 1991; 33(5):319-26. PubMed ID: 1651160
[TBL] [Abstract][Full Text] [Related]
3. Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients.
Faradji A; Bohbot A; Schmitt-Goguel M; Dumont S; Eischen A; Wiesel ML; Stierle A; Follea G; Eber M; Bergerat JP
Int J Artif Organs; 1991 May; 14(5):304-12. PubMed ID: 1864656
[TBL] [Abstract][Full Text] [Related]
4. Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis.
Stevenson HC; Keenan AM; Woodhouse C; Ottow RT; Miller P; Steller EP; Foon KA; Abrams PG; Beman J; Larson SM
Cancer Res; 1987 Nov; 47(22):6100-3. PubMed ID: 3117363
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
[TBL] [Abstract][Full Text] [Related]
9. Hemostatic changes in human adoptive immunotherapy with activated blood monocytes or derived macrophages.
Wiesel ML; Faradji A; Grunebaum L; Bohbot A; Schmitt-Goguel M; Bergerat JP; Cazenave JP; Oberling F
Ann Hematol; 1992 Aug; 65(2):75-8. PubMed ID: 1324742
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo activation of killer monocytes (AKM) and their application to the treatment of human cancer.
Stevenson HC; Lacerna LV; Sugarbaker PH
J Clin Apher; 1988; 4(2-3):118-21. PubMed ID: 3135291
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Meerpohl HG; Leser HG; Engler H; Löhr GW
Cancer Res; 1990 Dec; 50(23):7450-6. PubMed ID: 1701343
[TBL] [Abstract][Full Text] [Related]
12. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
Rossi CR; Foletto M; Mocellin S; Pilati P; De SM; Deraco M; Cavaliere F; Palatini P; Guasti F; Scalerta R; Lise M
Cancer; 2002 Jan; 94(2):492-9. PubMed ID: 11900234
[TBL] [Abstract][Full Text] [Related]
14. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron
Green DS; Nunes AT; David-Ocampo V; Ekwede IB; Houston ND; Highfill SL; Khuu H; Stroncek DF; Steinberg SM; Zoon KC; Annunziata CM
J Transl Med; 2018 Jul; 16(1):196. PubMed ID: 30012146
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.
Freedman RS; Vadhan-Raj S; Butts C; Savary C; Melichar B; Verschraegen C; Kavanagh JJ; Hicks ME; Levy LB; Folloder JK; Garcia ME
Clin Cancer Res; 2003 Nov; 9(14):5228-37. PubMed ID: 14614003
[TBL] [Abstract][Full Text] [Related]
17. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.
Kleinerman ES; Murray JL; Snyder JS; Cunningham JE; Fidler IJ
Cancer Res; 1989 Aug; 49(16):4665-70. PubMed ID: 2787207
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
19. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
